Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study
| العنوان: | Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study |
|---|---|
| المؤلفون: | Emanuela Anastasi, Valentina Viggiani, Lucia Manganaro, Sara Tartaglione, Teresa Granato, Serena Rita Zarrillo, Cinzia Marchese, Antonio Angeloni, Irene Pecorella |
| المصدر: | Biochemia Medica Volume 29 Issue 2 |
| بيانات النشر: | Croatian Society of Medical Biochemistry and Laboratory Medicine, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Clinical Biochemistry, pancreatic cancer, PIVKA-II, CA 19-9, CA 242, CEA, Enzyme-Linked Immunosorbent Assay, Pilot Projects, Vitamin k, Gastroenterology, Serology, 03 medical and health sciences, 0302 clinical medicine, Carcinoembryonic antigen, Interquartile range, Pancreatic cancer, Internal medicine, medicine, Biomarkers, Tumor, Humans, Protein Precursors, Aged, Aged, 80 and over, biology, Receiver operating characteristic, business.industry, Biochemistry (medical), Original Articles, Middle Aged, medicine.disease, 3. Good health, Pancreatic Neoplasms, ROC Curve, 030220 oncology & carcinogenesis, Luminescent Measurements, biology.protein, Biomarker (medicine), 030211 gastroenterology & hepatology, Female, Prothrombin, business, Biomarkers |
| الوصف: | Introduction: Protein induced by vitamin K absence II (PIVKA-II) is an abnormal prothrombin increased in gastrointestinal malignancy. We aimed to evaluate PIVKA-II in comparison to established pancreatic cancer (PC) biomarkers (CA 19-9, carcinoembryonic antigen (CEA) and CA 242) measured in PC patients and in patients with benign pancreatic diseases. Materials and methods: We studied 26 PC patients (Group 1) and 20 patients with benign pancreatic diseases (Group 2). PIVKA-II and CEA were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Gent, Belgium), CA 19-9 and CA 242 were measured by ELSA (CisBio Bioassays, Codolet, France) and EIA (Fujirebio Diagnostics AB, Göteborg, Sweden), respectively. Receiver operating characteristic (ROC) analysis was performed to assess biomarkers’ diagnostic characteristics in both groups. Results: Median and interquartile range (IQR) in Group 1 and Group 2 were: 1749.0 (320.2 – 3921.0) vs. 31.0 (23.0 – 43.0) mAU/mL (P < 0.001) for PIVKA-II, 260.0 (158.7 – 272.0) vs. 45.2 (9.0 – 58.0) U/mL (P = 0.034) for CA 19-9, 104.0 (30.2 – 150.0) vs. 7.2 (4.8 – 26.0) U/mL (P < 0.050) for CA 242, 9.4 (5.3 – 37.5) vs. 4.5 (1.8 – 7.0) ng/mL (P = 0.021) for CEA. Areas under the ROC curve of PIVKA-II, CA 19-9, CA 242, CEA were 0.86 (95% CI: 0.71 – 1.00), 0.58 (95% CI: 0.38 – 0.78), 0.73 (95% CI: 0.54 – 0.92), 0.64 (95% CI: 0.44 – 0.85), respectively. Conclusions: PIVKA-II is significantly higher in PC than in benign pancreatic diseases. PIVKA-II shows a rather good diagnostic performance compared to CA 19-9, CEA and CA242, thus its determination could help PC management. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1846-7482 1330-0962 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11d7adc4c965061f53b45c673eb0fa94Test http://europepmc.org/articles/PMC6559614Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....11d7adc4c965061f53b45c673eb0fa94 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18467482 13300962 |
|---|